Liraglutide Geriatric (65+) Safety: Risks, Dosing, and Monitoring

Saxenda and Victoza

Saxenda is liraglutide 3 mg once daily for weight management. Victoza is liraglutide up to 1.8 mg once daily for type 2 diabetes, and it also carries an indication to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [2][1]. Both are once-daily subcutaneous injections, not weekly [2][1]. Generic liraglutide is FDA-approved, with versions that reference Saxenda and versions that reference Victoza [3].

Is the dose different for adults 65 and older?

The Saxenda schedule: 0.6 mg once daily for one week, then weekly increases to 1.2 mg, 1.8 mg and 2.4 mg, reaching 3 mg daily from week 5. The label gives 3 mg as the recommended adult dose, says lower doses are for titration only, and says to discontinue if 3 mg is not tolerated [2]. The Victoza schedule: 0.6 mg daily for one week (a dose the label says is not effective for glycemic control in adults), then 1.2 mg, then 1.8 mg daily if more control is needed after at least another week, which is the maximum [1].

Neither label's dosing instructions give a different starting dose, titration interval or target dose for adults 65 and older [2][1]. The alternate schedules are pediatric: Saxenda escalation may take up to 8 weeks in patients aged 12 and older, and the dose may be reduced to 2.4 mg if 3 mg is not tolerated [2]. For a missed Saxenda dose, the label says to take the next scheduled dose and not to double up; if more than 3 days have passed, treatment restarts at 0.6 mg and is titrated again [2]. For adults, the Saxenda label also directs a weight check at 16 weeks, with discontinuation if less than 4% of baseline weight has been lost [2].

Gastrointestinal effects

In the Saxenda adult trials (5 placebo-controlled trials, 3,384 people on Saxenda vs 1,941 on placebo, up to 56 weeks at 3 mg), nausea occurred in 39.3% vs 13.8%, diarrhea in 20.9% vs 9.9%, constipation in 19.4% vs 8.5% and vomiting in 15.7% vs 3.9%. About 68% vs 39% reported any gastrointestinal disorder, nausea declined as treatment continued, and 9.8% vs 4.3% stopped for adverse reactions, most often nausea (2.9% vs 0.2%), vomiting (1.7% vs less than 0.1%) and diarrhea (1.4% vs 0%) [2].

In the Victoza type 2 diabetes trials, nausea occurred in 18% at 1.2 mg and 20% at 1.8 mg vs 5% on placebo, and severe gastrointestinal reactions in 4.4% and 4.2% vs 1.1% [1]. Both labels say liraglutide is not recommended in people with severe gastroparesis [2][1].

Kidney risk from dehydration

The Victoza label describes postmarketing acute kidney injury, some cases requiring hemodialysis, mostly in patients who had nausea, vomiting or diarrhea leading to dehydration. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1]. The Saxenda label has a matching warning for acute kidney injury due to volume depletion [2].

The largest look at kidney outcomes comes from LEADER, which randomized 9,340 adults with type 2 diabetes and high cardiovascular risk to liraglutide (1.8 mg target) or placebo over a median 3.84 years [4][5]. The composite renal outcome occurred in 268 of 4,668 on liraglutide vs 337 of 4,672 on placebo (hazard ratio 0.78, 95% CI 0.67 to 0.92), driven mainly by new persistent macroalbuminuria (161 vs 215; hazard ratio 0.74, 95% CI 0.60 to 0.91). Acute kidney injury rates were similar: 7.1 vs 6.2 events per 1,000 patient-years [5].

Hypoglycemia with insulin or a sulfonylurea

In the Saxenda label's type 2 diabetes trial, among adults taking a sulfonylurea, glucose below 54 mg/dL occurred in 31 of 110 on Saxenda (28.2%) vs 7 of 55 on placebo (12.7%); sulfonylurea doses were cut 50% at the start of the trial per protocol. Severe hypoglycemia needing another person's help occurred in 3 of 422 Saxenda patients (0.7%), all of whom were taking a sulfonylurea [2]. In the Victoza trials, hypoglycemia requiring assistance occurred in 8 liraglutide-treated patients, 7 of them on a sulfonylurea [1].

Both labels state that the risk may be lowered by reducing the dose of the sulfonylurea or insulin [2][1]. The Victoza label also says the pen must never be shared between patients, and that when liraglutide is used with insulin the two are given as separate injections and never mixed [1].

Heart rate and cardiovascular outcomes

On the Saxenda label, mean resting heart rate rose 2 to 3 bpm compared with placebo. More patients had a rise from baseline above 10 bpm at two consecutive visits (34% vs 19%) and above 20 bpm (5% vs 2%), and at least one resting rate above 100 bpm was recorded in 6% vs 4%. The label says to monitor heart rate at regular intervals [2].

LEADER enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk, with a median follow-up of 3.8 years. The primary composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 13.0% on liraglutide vs 14.9% on placebo (hazard ratio 0.87, 95% CI 0.78 to 0.97; P=0.01 for superiority), cardiovascular death in 4.7% vs 6.0% and death from any cause in 8.2% vs 9.6% [4]. Victoza is indicated to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]; Saxenda is not indicated for cardiovascular risk reduction [2].

Weight loss in the trials

SCALE Obesity and Prediabetes randomized 3,731 adults without diabetes to liraglutide 3 mg or placebo for 56 weeks. Mean weight loss was 8.4 kg vs 2.8 kg by last observation carried forward [6]. The Saxenda label reports 7.4% vs 3.0% of body weight lost, with 62.3% vs 34.4% losing at least 5% [2]. The trial's baseline mean age was 45.1 years [6]. SCALE Diabetes, 846 adults with type 2 diabetes over 56 weeks, found 6.0% weight loss with 3.0 mg vs 2.0% with placebo [7].

Thyroid, pancreas, gallbladder and mood

Both Saxenda and Victoza carry a boxed warning: liraglutide causes dose- and duration-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures, and human relevance is unknown. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value, and the Saxenda label advises counseling on symptoms such as a neck mass, trouble swallowing, shortness of breath or persistent hoarseness [2][1].

For pancreatitis, the Saxenda label says to discontinue if pancreatitis is suspected [2]. Gallbladder events in Saxenda adult trials: cholelithiasis 2.2% vs 0.8% and cholecystitis 0.8% vs 0.4%, with the label noting the incidence was higher than placebo even after accounting for the degree of weight loss [2].

On mood, FDA reviewed a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials (107,910 patients) and a claims cohort of 2,243,138 new users and found no increased risk of suicidal ideation or behavior. On 2026-01-13 it asked the makers of Saxenda, Wegovy and Zepbound to remove that warning, and the Saxenda label effective 2026-02-25 no longer contains it [9][2]. The Victoza label does not include it [1].

Interactions and what the labels say to monitor

Liraglutide delays gastric emptying. In clinical pharmacology trials it did not affect absorption of the tested oral medicines to a clinically relevant degree. The Saxenda label says to monitor for consequences of delayed absorption, and the Victoza label says caution should be exercised when oral medicines are taken with it [2][1]. With a combined oral contraceptive (0.03 mg ethinylestradiol/0.15 mg levonorgestrel), liraglutide lowered ethinylestradiol peak concentration 12% and levonorgestrel 13%, left ethinylestradiol AUC unchanged, raised levonorgestrel AUC 18% and delayed time to peak by 1.5 hours. The Saxenda label gives no instruction to add or switch contraception [2].

Monitoring the labels specify:

• Renal function in anyone reporting gastrointestinal reactions that could lead to volume depletion, especially during initiation and escalation [1][2].
• Heart rate at regular intervals (Saxenda) [2].
• Blood glucose before and during Saxenda treatment in adults with type 2 diabetes [2].
• Signs of pancreatitis and gallbladder disease [2].
• Both labels instruct patients to tell their healthcare providers about planned surgery or procedures, since pulmonary aspiration has been reported with GLP-1 receptor agonists during general anesthesia or deep sedation [2][1].